AVE 1642

Drug Profile

AVE 1642

Alternative Names: AVE1642

Latest Information Update: 16 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Developer sanofi-aventis
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Multiple myeloma; Solid tumours

Most Recent Events

  • 11 May 2009 Discontinued - Phase-I for Multiple myeloma in Europe (Parenteral)
  • 11 May 2009 Discontinued - Phase-I for Solid tumours in Europe (Parenteral)
  • 30 Apr 2009 Discontinued - Phase-II for Breast cancer in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top